SeraCare acquires Celliance manufacturing, product assets

By Angela McDaniels

Seattle, Nov. 29 - SeraCare Life Sciences Inc. said it has agreed to buy the Milford, Mass., diagnostic manufacturing facilities and product lines of Celliance, a subsidiary of Serologicals Corp., for $3.7 million in cash and the assumption of selected liabilities.

"This acquisition will increase our portfolio of products in the areas of molecular diagnostic reagents, diagnostic intermediates and substrates," Michael F. Crowley, SeraCare president and chief executive officer, said in a company news release.

"In connection with this acquisition, we will assume the lease on Celliance's state-of-the-art manufacturing, storage and distribution facility located near our West Bridgewater manufacturing site. We believe the proximity of these two diagnostic manufacturing facilities will allow us to achieve synergies in the areas of manufacturing, staffing and distribution."

SeraCare expects the acquisition to be accretive to earnings by the first fiscal quarter following the closing of the acquisition, which, subject to the satisfaction of customary closing conditions, is expected to be completed in January.

SeraCare is an Oceanside, Calif.-based manufacturer and supplier of biological materials and services for the use and manufacture of diagnostic tests and the development of pharmaceuticals.

Celliance develops cell culture and diagnostic products and provides contract services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.